The MMRC is a unique research model that was developed to accelerate the development of novel, cutting-edge treatments for patients afflicted by multiple myeloma by catalyzing, promoting, and facilitating collaborative research between industry and academia. Founded in 2004, the MMRC now stands as an optimal model to fast-track promising myeloma therapies out of the research lab and into clinic where patients can benefit.
The MMRC is comprised of fifteen world-renowned Member Institutions:
Researchers from these institutions are conducting innovative research efforts in three Research Cores that span the most exciting areas of myeloma research: A state-of-the-art Data Bank enables the standardization and sharing of clinical and research data to facilitate research efforts among Consortium researchers and across Member Institutions.
Committed to bringing new treatments to patients as quickly as possible, MMRC research and drug development efforts are highly focused on the robust validation of new and combination therapies and advancing these compounds into high-quality, Phase I and II clinical trials.
The MMRC is comprised of fifteen world-renowned Member Institutions:
- Dana-Farber Cancer Institute
- H. Lee Moffitt Cancer Center & Research Institute
- Mayo Clinic Cancer Center
- City of Hope National Medical Center
- Emory University
- Hackensack University Medical Center
- Indiana University Simon Cancer Center
- Ohio State University Comprehensive Cancer Center
- Roswell Park Cancer Institute
- Saint Vincent Catholic Medical Centers of New York
- University Health Network (Princess Margaret Hospital)
- University of California, San Francisco
- University of Chicago
- University of Michigan, Ann Arbor
- Washington University in St. Louis
Researchers from these institutions are conducting innovative research efforts in three Research Cores that span the most exciting areas of myeloma research: A state-of-the-art Data Bank enables the standardization and sharing of clinical and research data to facilitate research efforts among Consortium researchers and across Member Institutions.
Committed to bringing new treatments to patients as quickly as possible, MMRC research and drug development efforts are highly focused on the robust validation of new and combination therapies and advancing these compounds into high-quality, Phase I and II clinical trials.
